The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma
Ling‐Long Tang, Yu‐Pei Chen, Chuanben Chen, Ming‐Yuan Chen, Nian‐Yong Chen, Xiaozhong Chen, Xiaojing Du, Wen‐Feng Fang, Mei Feng, Jin Gao, Fei Han, Xia He, Chaosu Hu, Desheng Hu, Guang‐Yuan Hu, Hao Jiang, Wei Jiang, Feng Jin, Jinyi Lang, Jingao Li, Shaojun Lin, Xu Liu, Qiu‐Fang Liu, Lin Ma, Hai‐Qiang Mai, Jiyong Qin, Liangfang Shen, Ying Sun, Peiguo Wang, Rensheng Wang, Ruozheng Wang, Xiao‐Shen Wang, Ying Wang, Hui Wu, Yunfei Xia, Shaowen Xiao, Kunyu Yang, Junlin Yi, Xiaodong Zhu, Jun Ma
Abstract
Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these comprehensive guidelines for the diagnosis and management of NPC, the Chinese Society of Clinical Oncology (CSCO) arranged a multi-disciplinary team comprising of experts from all sub-specialties of NPC to write, discuss, and revise the guidelines. Based on the findings of evidence-based medicine in China and abroad, domestic experts have iteratively developed these guidelines to provide proper management of NPC. Overall, the guidelines describe the screening, clinical and pathological diagnosis, staging and risk assessment, therapies, and follow-up of NPC, which aim to improve the management of NPC.